Drugs / HBI0101 CART
HBI0101 CART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07085676 | Sep 2024 → Nov 2026 expected | antiphospholipid syndrome, idiopathic inflammatory myopathy, myasthenia gravis, neuromyelitis optica spectrum disorder with anti-AQP4 antibodies +5 | Polina Stepensky | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06971380 | Mar 2025 → May 2028 expected | AL amyloidosis, plasma cell myeloma | Polina Stepensky | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBI0101 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06971380 ↗ |
| Known as | HBI0101 BCMA-CART | “A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases.” NCT07085676 ↗ |
| Known as | NXC-201 | “Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis” NCT06971380 ↗ |
| Modality | Cell therapy | “HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA.” NCT06971380 ↗ |